TKNO vs. ZYME, AMLX, SION, TLRY, PHVS, AMPH, EVO, ATAI, TRML, and CVAC
Should you be buying Alpha Teknova stock or one of its competitors? The main competitors of Alpha Teknova include Zymeworks (ZYME), Amylyx Pharmaceuticals (AMLX), Sionna Therapeutics (SION), Tilray Brands (TLRY), Pharvaris (PHVS), Amphastar Pharmaceuticals (AMPH), Evotec (EVO), atai Life Sciences (ATAI), Tourmaline Bio (TRML), and CureVac (CVAC). These companies are all part of the "pharmaceutical products" industry.
Alpha Teknova vs. Its Competitors
Zymeworks (NYSE:ZYME) and Alpha Teknova (NASDAQ:TKNO) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, earnings, risk, dividends, analyst recommendations, media sentiment, institutional ownership and valuation.
92.9% of Zymeworks shares are held by institutional investors. Comparatively, 13.8% of Alpha Teknova shares are held by institutional investors. 1.9% of Zymeworks shares are held by insiders. Comparatively, 12.5% of Alpha Teknova shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Zymeworks has a beta of 1.51, suggesting that its share price is 51% more volatile than the S&P 500. Comparatively, Alpha Teknova has a beta of 0.41, suggesting that its share price is 59% less volatile than the S&P 500.
In the previous week, Zymeworks had 3 more articles in the media than Alpha Teknova. MarketBeat recorded 3 mentions for Zymeworks and 0 mentions for Alpha Teknova. Zymeworks' average media sentiment score of 1.10 beat Alpha Teknova's score of 0.00 indicating that Zymeworks is being referred to more favorably in the media.
Alpha Teknova has lower revenue, but higher earnings than Zymeworks. Zymeworks is trading at a lower price-to-earnings ratio than Alpha Teknova, indicating that it is currently the more affordable of the two stocks.
Alpha Teknova has a net margin of -55.24% compared to Zymeworks' net margin of -182.75%. Zymeworks' return on equity of -23.00% beat Alpha Teknova's return on equity.
Zymeworks presently has a consensus target price of $21.43, indicating a potential upside of 29.87%. Alpha Teknova has a consensus target price of $10.00, indicating a potential upside of 90.84%. Given Alpha Teknova's higher probable upside, analysts clearly believe Alpha Teknova is more favorable than Zymeworks.
Summary
Zymeworks beats Alpha Teknova on 11 of the 16 factors compared between the two stocks.
Get Alpha Teknova News Delivered to You Automatically
Sign up to receive the latest news and ratings for TKNO and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding TKNO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Alpha Teknova Competitors List
Related Companies and Tools
This page (NASDAQ:TKNO) was last updated on 10/7/2025 by MarketBeat.com Staff
